Metabolic

Semaglutide

GLP-1 receptor agonist

Studied forWeight management · fatty liver disease1 2

Community reportsAppetite7

FDA-approved prescription products for specific diabetes and weight-management uses; Wegovy also has cardiovascular-risk and MASH indications. Product and population matter.

What does it do?

A GLP-1 medicine with product-specific diabetes, weight and other approved indications; research vials are not approved products.

Approved & studied uses

Weight management

1 2

Wegovy studies and approvals cover defined populations and formulations.

MASH

Wegovy has accelerated approval for adults with specified liver fibrosis.

Community uses Reported, unvalidated

Weight

Appetite, cravings and maintenance; oral/injectable product evidence differs.

Diabetes / cardiovascular

Glycemic control and cardiovascular outcomes.

Metabolic

Liver disease, insulin sensitivity, lipids and inflammation research.

Reasons people report using it; these do not establish benefit.18

Evidence limits

View research →

Trial averages do not predict individual weight loss or tolerance.1

4 distinct primary sources or abstracts checked. Evidence may concern a parent compound, individual blend ingredient, animal, or cell model; it does not necessarily establish a benefit for this exact product.

Evidence definitions →

Key safety information

All risks →

Common effects

Gastrointestinal symptoms include nausea, vomiting, diarrhea and constipation.3

FDA-approved prescription products for specific diabetes and weight-management uses; Wegovy also has cardiovascular-risk and MASH indications. Product and population matter.

Molecular information

5 3

Amino-acid sequence

His
Aib
Glu
Gly
Thr
Phe
Thr
Ser
Asp
Val
Ser
Ser
Tyr
Leu
Glu
Gly
Gln
Ala
Ala
Lys*
Glu
Phe
Ile
Ala
Trp
Leu
Val
Arg
Gly
Arg
Gly

31 residues · N → C16

Length31 amino acids

Molecular weight · Da4113.58 Da

Formula, sequence notation & identity

Molecular formulaC₁₈₇H₂₉₁N₄₅O₅₉5 3

H–Aib–E–G–T–F–T–S–D–V–S–S–Y–L–E–G–Q–A–A–K*–E–F–I–A–W–L–V–R–G–R–G

Aib replaces alanine at sequence position 2. K* at sequence position 20 carries semaglutide’s acylated side chain. Positions are counted within this 31-residue sequence.

Lipidated GLP-1 analogue.

Chemical properties refer to semaglutide, not an unspecified salt or retail powder.

Pep-Pedia identity details

31 amino acids · 4,113.64 Da

His-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Arg-Gly-Arg-Gly

Reference description; checked chemical identity above takes precedence when available.18

Pharmacokinetics

How long does it stay in the body?

Data shown

Human data

Reported half-lifeApproximately 1 week3

Route / formulationSubcutaneous Wegovy

Elapsed time 7 d

50%of reference level

Illustrative model using reported human data.

About 3% remaining after 35 d

Five half-lives in this simplified model. This is not a prediction of when effects stop.

Evidence and model details

Label elimination estimate. Oral and injectable products have different absorption and are not mg-for-mg substitutes.

Population: Patients with overweight or obesity

100 × 2^{−time / half-life}. Time zero is a reference level, not the moment of administration. Absorption, repeated dosing, metabolites and clinical effects are not modeled. Five half-lives leaves 3.125%, not zero. This curve cannot determine a dosing interval.

What to expect

Study outcomes

Weight reduction over 68 weeks

STEP 1 mean weight change was −14.9% with semaglutide versus −2.4% with placebo.1

Reported timelines

Reference & community

Source expectations

Glucose 1–4 weeks; weight changes accumulate over 2–6+ months. Source percentage ranges are not individual forecasts.18

These are reported timelines, not a prediction of your response.

Community poll 10 topics · Pep-Pedia snapshot

Voluntary, unverified reports. These percentages do not measure effectiveness or safety.

Topic

Primary goal

Fat loss97%

General wellness3%

Number of responses to this question: not disclosed.

Source & limitations

The source displays “329 responses” for this profile. This is not a confirmed participant count or a denominator for individual questions.

Voluntary self-reports from Pep-Pedia visitors; identity, treatment, outcomes and timing are unverified. These data are not efficacy or safety estimates.
The source displays a profile-wide response label, not a confirmed unique participant count. It stays unchanged across questions. Question-specific denominators and absolute option counts are not exposed.
Only the top five categories are displayed for some questions. Extra categories are retained as an undisplayed-category count; their labels and percentages are unavailable.
Displayed percentages are rounded. They may not total 100%, especially where categories are hidden.
This is a dated snapshot, not a live survey or current recommendation.

Protocols

Doses & schedules

Compare purpose, amount, route, frequency, and duration.

Source corrections

Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams.

Route

Scroll to compare all columns →

One row for each documented route and dose or dose range
Route	Dose	Frequency	Goal / evidence	Duration	References
SubQSubcutaneous	2.4 mg target	Once weekly	Weight reduction: STEP 1Human study	68 weeks	1
Population 1,961 adults with obesity/overweight without diabetes Context Target followed escalation; all groups received lifestyle intervention.
SubQ	0.25 mg	Weekly x 4 weeks, then increase	Weight Loss InitiationReference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable
SubQ	2.4 mg	Weekly (after 16-week titration)	Weight Loss MaintenanceReference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable
SubQ	0.5-1 mg	Weekly	Diabetes ManagementReference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable
SubQ	0.5-1 mg	Weekly	Cardiovascular ProtectionReference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable
SubQ	0.25-2.4 mg	Weekly (individualized)	Tolerability-BasedReference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Injectable
OralOral (empty stomach)	3 mg	Daily x 30 days	Diabetes Initiation (Rybelsus)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	7 mg	Once daily	Standard Diabetes Dose (Rybelsus)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	14 mg	Once daily	Maximum Diabetes Dose (Rybelsus)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	1.5 mg	Daily x 4 weeks	Weight Loss Initiation (Oral Wegovy)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	4 mg	Daily x 4 weeks	Weight Loss Escalation 1 (Oral Wegovy)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	9 mg	Daily x 4 weeks	Weight Loss Escalation 2 (Oral Wegovy)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	25 mg	Once daily	Weight Loss Maintenance (Oral Wegovy)Reference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral
OralOral (empty stomach)	3-7 mg	Daily (no adjustment needed)	Renal ImpairmentReference report	Ongoing treatment as prescribed	18
Population Population not independently verified; see the reference and linked research. Context Reported in Pep-Pedia’s educational protocol table. Study attribution and applicability to this exact product are not independently established. Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams. Source tabs Oral

Study and label doses retain their study context. Reference reports are unvalidated practices, not personal treatment instructions. Ranges remain ranges; escalation stages are labeled.

Cycles & timing

Reference reports18

Reported use periods and breaks. These do not establish a safe cycle or prove that breaks prevent tolerance.

Injectable

Use period: Ongoing treatment as prescribed
Break: Not applicable - continuous therapy

Reported timing

Any time of day, with or without food

Oral

Use period: Ongoing treatment as prescribed
Break: Not applicable - continuous therapy

Reported timing

First thing in morning, 30+ min before food/drink/meds

Side effects & safety

Common effects

Gastrointestinal symptoms include nausea, vomiting, diarrhea and constipation.

Thyroid warning

Contraindicated with personal/family MTC or MEN2; human tumor risk is unknown.

Serious risks

Warnings include pancreatitis, gallbladder disease and dehydration-related kidney injury.

Pregnancy planning

Label specifies discontinuation at least 2 months before a planned pregnancy.

Additional reported cautions

Reference reports18

Common

GI symptoms, fatigue, headache, hair loss and altered skin sensations.

Key risks

MTC/MEN2 contraindication; pancreatitis, gallbladder disease, dehydration/kidney injury, retinopathy, aspiration and pregnancy risks.

Urgent

Abdominal pain, jaundice, neck swelling, dyspnea/allergy, low urine, vision changes, confusion or fainting.

Not a complete safety screen. Discuss health decisions with a qualified clinician.

Combinations & interactions

12 entries

Check cautions and reported pairings. A compatibility claim does not establish that a combination is safe.

Insulin

Caution reported

Hypoglycemia.18

Reference report · Pep-Pedia label: Monitor Combination

Sulfonylureas

Caution reported

Hypoglycemia.18

Reference report · Pep-Pedia label: Monitor Combination

Tirzepatide

Avoidance reported

Incretin duplication.18

Reference report · Pep-Pedia label: Avoid Combination

Retatrutide

Avoidance reported

GLP-1 duplication.18

Reference report · Pep-Pedia label: Avoid Combination

Oral drugs

Caution reported

Product-specific absorption instructions.18

Reference report · Evidence context: Requires timing

Insulin or sulfonylureas

Label warning

Increased hypoglycemia risk.3

Research context

Other semaglutide or GLP-1 products

Label warning

Wegovy coadministration is not recommended.3

Research context

Oral medicines

Label warning

Delayed gastric emptying may affect absorption; monitoring can be needed.3

Research context

Cagrilintide

Unverified pairing

Studied as CagriSema, not homemade stack.18

Reference report · Pep-Pedia label: Synergistic

Metformin

Unverified pairing

Established co-treatment.18

Reference report · Pep-Pedia label: Compatible

GH peptides

Unverified pairing

Untested pairing.18

Reference report · Evidence context: Compatible

BPC-157

Unverified pairing

No proven GI protection.18

Reference report · Pep-Pedia label: Compatible

Reconstitution calculator

Enter your peptide amount and container size. Get a volume and a simple measurement scale.

1How much peptide do you have?

Total labeled amount of Semaglutide.

2How much can your container hold?

Usable capacity of the destination vial or pen cartridge.

Measure with

1 dial unit = 0.01 mL on the documented V2 model. Confirm your pen’s scale.

Vial examples & blend contents Semaglutide

Peptide reference

Listed amounts are packaging examples. Check your actual label.

Suggested final volume mL

Estimated water to add≈ mL

For dry powder, assuming negligible volume displacement. Use bacteriostatic water only if the formulation specifies it.

1 pen unit (one dial step)=

Measurement scale Conversions, not recommended doses
Pen units	Amount	Volume

Other simple scales

Convert a specific amount

Enter an amount to calculate its volume and device setting.

Amount to measure

Measuring-tool capacity

Calculation & assumptions

The suggestion favors a simple 1, 2, or 5 × power-of-ten amount per unit, then the largest final volume that fits. It does not choose a dose or a biologically suitable concentration.

The water estimate applies only to dry powder and assumes negligible powder displacement. Final solution volume, specified diluent, solubility, stability, sterility, cartridge compatibility, and working fill limits must be established separately. No allowance is made for priming or transfer losses.

V2 measurement specification ↗Bacteriostatic water: formulation instructions ↗

Reconstitution

Ready-to-use approved injection

Wegovy injectable pens contain solution; no reconstitution.3

Product distinction

Research powder and compounded salts are not the labeled pen formulation.3

Reference preparation details

Reported handling information, not a validated formulation or instruction to prepare an injectable product.

Injectable

The source describes a ready-made pen or vial, not a dry-powder mixing protocol.

Form: Source describes a prepared product

Pen priming, hold time, refrigeration and in-use expiry vary by branded presentation. The source’s 28-day storage line is not universal.

Oral

The source describes oral-tablet handling.

Form: Source describes a prepared product
Reported parameters: Reported timing: morning on an empty stomach, with no more than 4 ounces of plain water. · Reported waiting interval: at least 30 minutes before food, drink or other oral medicines; tablet swallowed intact.

Appearance & documentation

Appearance and a purity certificate cannot establish sterility, identity, or suitability for injection.

Reported appearanceFDA-approved branded productsReported appearanceProper storage verificationReported appearanceClear solution in pen/vialReported variationCompounded versionsReported concernCloudy or discolored solutionReported concernNon-pharmacy sources

Vial sizes

2mg8

5mg8

10mg8

15mg8

20mg8

Packaging examples, not a market survey. Approved and research products are not interchangeable.

Storage after mixing

Reconstituted research vials

Refrigerated lifetime not established

The checked sources do not establish how long this research preparation remains stable and sterile after mixing.18

Ready-made products

Product-specific storage; no reconstitution.

Ozempic multi-dose pen

Before first use: 2–8°C. After first use: 56 days at 15–30°C or 2–8°C. Do not freeze; protect from heat and light.19

Ozempic single-dose syringe

Normally 2–8°C; up to 28 days at 8–30°C in the original carton. Discard after use.19

Wegovy single-dose pen / syringe

Normally 2–8°C; before cap removal, up to 28 days at 8–30°C in the original carton. Do not freeze; discard after use.20

Wegovy FlexTouch multi-dose pen

Before first use: 2–8°C. After first use: up to 56 days at 15–30°C or 2–8°C. Do not freeze; protect from heat and light.20

Wegovy tablets

20–25°C, dry, in the original closed bottle. These product-specific rules do not establish expiry for a reconstituted research vial.20

Full storage notes from Pep-Pedia

Injectable

Refrigerate before first use, then refrigerate or room temp up to 28 days

Oral

Room temperature in original blister pack

Storage depends on the formulation, diluent, container, and handling. Follow the specific product label or pharmacist’s instructions.

Pen & syringe measurements Scales, capacity & references

Pen & syringe measurements

Device units measure volume. Concentration determines the amount in mg.

Open calculator ↗

V2 peptide pen

1 notch = 0.01 mL

Documented 1-unit V2 models

One dial increment: 1 unit
Cartridge capacity: 3 mL
Maximum setting: 60 units · 0.60 mL

Use the numbered dose window. Whole-unit settings only; confirm the specification for your exact model.

U-100 syringe

1 unit = 0.01 mL

100 units = 1 mL

10 units: 0.10 mL
30-unit capacity: 0.30 mL
50 / 100-unit capacity: 0.50 / 1 mL

Read the printed unit scale. A small line may represent 0.5, 1, or 2 units depending on the syringe.

Other measuring tools

Use the mL scale

mL syringes and calibrated pipettes

0.01 mL: 10 µL
0.10 mL: 100 µL
Amount: mL × mg/mL

Drops, sprays and other pen clicks need their own verified volume per increment. They have no universal conversion.

3 mL is cartridge capacity. It does not mean you must prepare or load 3 mL. The original vial and the pen cartridge are different containers. This reference compares measurement scales; it does not establish product or route compatibility.

Device references

AVERON V2 specifications ↗SilverLeaf V2 unit reference ↗FDA: syringe unit conversions ↗Specifications checked October 12, 2026.

Research findings

Human trials

Source context

Approval and oral instructions depend on formulation; injectable milligrams cannot be substituted for oral milligrams.

Compound identity & other names

A GLP-1 receptor agonist studied in large human trials. Its prescription products have different indications and formulations; dose amounts cannot be transferred between oral, injectable and research products.

Other names: Sema · Ozempic · Wegovy · Rybelsus · Wegovy HD

FDA-approved prescription products for specific diabetes and weight-management uses; Wegovy also has cardiovascular-risk and MASH indications. Product and population matter.

How it may work

Glucose-dependent insulin secretion, glucagon suppression, appetite regulation and delayed gastric emptying; oral absorption uses SNAC.18

STEP 1: 14.9% versus 2.4%

In 1,961 adults without diabetes, weekly 2.4 mg plus lifestyle support produced 14.9% mean weight loss at 68 weeks, versus 2.4% with placebo plus lifestyle support.

Product-specific indications

FDA approved Wegovy HD 7.2 mg injection in March 2026 for weight loss and maintenance in eligible adults. Older 2.4 mg studies remain evidence for that specific regimen, not the entire current product range.

Higher-dose STEP UP trial

In adults without diabetes, 72-week weight change was −18.7% with 7.2 mg and −15.6% with 2.4 mg (treatment-policy estimand). Dysaesthesia and GI events were more common with the higher dose.

Source checks & newer research

Ozempic prescribing information: presentation-specific storage

May 2026 label: multi-dose pen after first use 56 days at 15–30°C or 2–8°C; single-dose syringe 28 days at 8–30°C. Protect from light; do not freeze. Does not establish research-vial stability.

Approved product label19

Wegovy prescribing information: storage and indications

June 2026 label: capped single-dose pen/syringe 28 days at 8–30°C; FlexTouch multi-dose pen 56 days after first use at 15–30°C or 2–8°C. Tablets 20–25°C in original dry bottle. Injectable has a noncirrhotic MASH F2–F3 indication; oral indications differ.

Approved product label20

Research areas and evidence gaps

Weight management. Wegovy studies and approvals cover defined populations and formulations.1 2

MASH. Wegovy has accelerated approval for adults with specified liver fibrosis.4

Trial averages do not predict individual weight loss or tolerance.
This profile highlights selected studies and indications; it is not a complete prescribing label.

Community reports Unvalidated

Pep-Pedia discusses appetite control and weight management. Its protocol table is secondary and does not capture every current approved semaglutide formulation.7

A secondary protocol description, not a clinical recommendation or a representative survey. Dose, product identity, other compounds and outcome reporting are not independently verified.

Search coverage and review status

The targeted check identified relevant additional literature or current regulatory information; checked findings are separated from retained bibliography-only references.

Checked: 2026-10-12
Search: semaglutide 2026 trial STEP UP 7.2 site:pubmed.ncbi.nlm.nih.gov
Catalog: Pep-Pedia ↗ · 7 listed references retained

Targeted search, not an exhaustive systematic review.
Bibliography-only entries are retained for traceability and are not treated as verified findings.

AI-prepared summaries. Independent medical editorial review is pending.

References

Original sources and review status. Open a reference to read its summary.

20 sources

1STEP 1: once-weekly semaglutide in adults with overweight or obesityTrial · 2021 · pubmed.ncbi.nlm.nih.govReview status not recorded

AI-PREPARED SUMMARY

Randomized 68-week trial: average weight loss was 14.9% with 2.4 mg weekly plus lifestyle support and 2.4% with placebo plus lifestyle support.

STEP 1: 14.9% versus 2.4%

In 1,961 adults without diabetes, weekly 2.4 mg plus lifestyle support produced 14.9% mean weight loss at 68 weeks, versus 2.4% with placebo plus lifestyle support.

Original source

2FDA: higher-dose semaglutide approvalRegulator · 2026 · fda.govReview status not recorded

AI-PREPARED SUMMARY

FDA approved Wegovy HD 7.2 mg injection for weight reduction and maintenance in eligible adults on March 19, 2026.

Product-specific indications

Original source

3Wegovy FDA prescribing information, 2026Regulator · 2026 · accessdata.fda.govReview status not recorded

AI-PREPARED SUMMARY

Product-specific prescribing information. Review it for current indications, presentations, contraindications and warnings.

Original source

4FDA: Wegovy approval for MASHRegulator · 2025 · content.govdelivery.comReview status not recorded

AI-PREPARED SUMMARY

The expanded indication covers adults with MASH and moderate-to-advanced liver fibrosis; it is not an approval for all liver disease.

Original source

5PubChem: semaglutide chemical identityRegistry · 2026 · pubchem.ncbi.nlm.nih.govReview status not recorded

AI-PREPARED SUMMARY

Identifies semaglutide as a modified 31-residue peptide and records its formula.

Original source

6STEP UP: once-weekly semaglutide 7.2 mg in adults with obesityTrial · 2025 · pubmed.ncbi.nlm.nih.govAbstract checked

AI-PREPARED SUMMARY

72-week phase 3b trial: treatment-policy mean weight change −18.7% with 7.2 mg versus −15.6% with 2.4 mg and −3.9% placebo; dysaesthesia and GI events were more frequent at 7.2 mg.

Higher-dose STEP UP trial

In adults without diabetes, 72-week weight change was −18.7% with 7.2 mg and −15.6% with 2.4 mg (treatment-policy estimand). Dysaesthesia and GI events were more common with the higher dose.

Additional research · Checked 2026-10-12

Original source

7Pep-Pedia: semaglutide — community referenceCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Accessed October 12, 2026. Reports commonly discussed protocols; these schedules are unvalidated descriptions, not evidence of safety or efficacy.

Original source

8Research catalog: labeled vial examplesCatalog · 2026 · leewaygo.comCatalog checked

AI-PREPARED SUMMARY

Catalog lists research vials including 2, 5, 10, 15, 20 mg. Seller labels only: contents and suppliers are not independently verified or endorsed, and these are not market-frequency estimates.

Original source

9OASIS 4 Oral Semaglutide for Weight Management (2025)Research reference · 2025 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The oral trial is described as producing about 14% versus 2.4% weight loss over 64 weeks in adults without diabetes; approved-product details need a label.

Reported population / model
307 participants

Reported study details
25mg daily · 64 weeks · ~14% weight loss (~33 lb) vs 2.4% placebo

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

10SELECT Cardiovascular Outcomes (2023)Research reference · 2023 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The cardiovascular trial found a reported 20% relative reduction in major events in people with established cardiovascular disease; absolute risk also matters.

Reported population / model
17,604 participants

Reported study details
2.4mg weekly · 5 years · 20% CV risk reduction

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

11STEP 5 Two-Year Maintenance (2022)Research reference · 2022 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The source reports 15.2% mean weight loss at 104 weeks with continued treatment in a 304-person study.

Reported population / model
304 participants

Reported study details
2.4mg weekly · 104 weeks · Sustained weight loss

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

12STEP TEENS Adolescent Study (2022)Research reference · 2022 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The adolescent trial reported a 16.1% reduction in BMI over 68 weeks; this is a pediatric obesity population with supervised care.

Reported population / model
201 adolescents

Reported study details
2.4mg weekly · 68 weeks · 16.1% BMI reduction

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

13STEP 1 Trial - Weight Management (2021)Research reference · 2021 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: Adults in STEP 1 lost an average 14.9% of weight versus 2.4% with placebo alongside lifestyle support.

Reported population / model
1,961 participants

Reported study details
2.4mg weekly · 68 weeks · 14.9% weight loss

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

14PIONEER Oral Semaglutide (2019)Research reference · 2019 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The oral diabetes program evaluated several doses and trials; pooled descriptions should not replace individual trial-specific HbA1c results.

Reported population / model
9,543 participants

Reported study details
3-14mg daily · 26-78 weeks · Oral efficacy

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

15SUSTAIN Diabetes Program (2016-2019)Research reference · 2019 · pep-pedia.orgPep-Pedia report · Primary source not checked

AI-PREPARED SUMMARY

Pep-Pedia reports: The injectable diabetes program reported HbA1c reductions around 1.5–1.8 points across studies; effects depend on baseline and comparator.

Reported population / model
Multiple trials

Reported study details
0.5-1mg weekly · Various durations · HbA1c reduction

Pep-Pedia supplies no original study link for this card. Study identity, design, doses and result remain unverified.

Read the Pep-Pedia report ↗

Pep-Pedia reference card; original summary of its reported findings · Checked 2026-10-12

Source report

16NIH NCATS GSRS: semaglutide sequence and substitutionsChemical identity · 2026 · gsrs.ncats.nih.govPrimary source checked

AI-PREPARED SUMMARY

Sequence and modifications checked October 12, 2026. Aib replaces alanine at sequence position 2. K* at sequence position 20 carries semaglutide’s acylated side chain. Positions are counted within this 31-residue sequence.

Original source

17Pep-Pedia: Semaglutide — reported pharmacokineticsReference estimate; not independently verified human PKCommunity · 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Lists a half-life of 7 days and a peak time of 1 day. Stated attribution: FDA Ozempic Label. This value is reported by a secondary reference. The stated attribution has not been independently verified as a route- and formulation-matched human PK measurement. Five half-lives is not complete clearance, and the source’s “cleared” value is not used as a measured endpoint.

Secondary reference page checked; the underlying quantitative claim is not independently confirmed. · Checked 2026-10-12

Original source

18Pep-Pedia: Semaglutide — route-specific referenceReference page checked; underlying claims require separate verification.Community · Checked 2026 · pep-pedia.orgCommunity source checked

AI-PREPARED SUMMARY

Source page checked across available routes. Protocols, cycles, storage, mechanisms and pairing claims are secondary reports; checking the page does not independently validate those claims. Original concise summaries are used here.

Content coverage audit · Checked 2026-10-12

Original source

19Ozempic prescribing information: presentation-specific storageRegulator · 2026 · novo-pi.comPrimary source checked

AI-PREPARED SUMMARY

Ozempic prescribing information: presentation-specific storage

Additional primary-source check · Checked 2026-10-12

Original source

20Wegovy prescribing information: storage and indicationsRegulator · 2026 · novo-pi.comPrimary source checked

AI-PREPARED SUMMARY

Wegovy prescribing information: storage and indications

Additional primary-source check · Checked 2026-10-12

Original source

What does it do?

Approved & studied uses

Weight management

MASH

Community uses Reported, unvalidated

Weight

Diabetes / cardiovascular

Metabolic

Evidence limits

Key safety information

Common effects

Molecular information

Amino-acid sequence

How long does it stay in the body?

What to expect

Study outcomes

Weight reduction over 68 weeks

Reported timelines

Source expectations

Experience

Duration of use

Age range

Gender

Primary goal

Effectiveness

Side effects

Dosage frequency

Would recommend

How discovered

Doses & schedules

Cycles & timing

Injectable

Reported timing

Oral

Reported timing

Side effects & safety

Common effects

Thyroid warning

Serious risks

Pregnancy planning

Additional reported cautions

Common

Key risks

Urgent

Combinations & interactions

Insulin

Sulfonylureas

Tirzepatide

Retatrutide

Oral drugs

Insulin or sulfonylureas

Other semaglutide or GLP-1 products

Oral medicines

Cagrilintide

Metformin

GH peptides

BPC-157

Reconstitution calculator

Ingredients per unit

Reconstitution

Product distinction

Injectable

Oral

Vial sizes

Storage after mixing

Reconstituted research vials

Ready-made products

Ozempic multi-dose pen

Ozempic single-dose syringe

Wegovy single-dose pen / syringe

Wegovy FlexTouch multi-dose pen

Wegovy tablets

Pen & syringe measurements

1 notch = 0.01 mL

1 unit = 0.01 mL

Use the mL scale

Research findings

Source context

STEP 1: 14.9% versus 2.4%

Product-specific indications